AnaptysBio, Inc.

Equities

ANAB

US0327241065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
21 ^USD	+11.29%		+5.69%	-1.96%

Apr. 16	Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	MT
Apr. 11	Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	MT

AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 11, 2024 at 04:36 pm EDT

AnaptysBio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 163.62 million compared to USD 128.72 million a year ago. Basic loss per share from continuing operations was USD 6.08 compared to USD 4.57 a year ago.

Latest news about AnaptysBio, Inc.

Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	Apr. 16	MT
Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	Apr. 11	MT
JPMorgan Adjusts Price Target on AnaptysBio to $28 From $30, Maintains Neutral Rating	Apr. 01	MT
AnaptysBio, Inc.(NasdaqGS:ANAB) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
AnaptysBio Shares Jump on Upgrade by Wedbush	Mar. 12	MT
Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20	Mar. 12	MT
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
BTIG Initiates Coverage on AnaptysBio With Buy Rating, $55 Price Target	Feb. 26	MT
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	Feb. 16	MT
Piper Sandler Initiates AnaptysBio at Overweight Rating With $80 Price Target	Feb. 16	MT
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
GSK: EU approves Jemperli for endometrial cancer	Dec. 11	CF
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	Nov. 27	MT
Wedbush Lifts AnaptysBio's PT to $20 From $18 Due to Updated Cash Guidance, Keeps Neutral Rating	Nov. 03	MT
AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
UBS Cuts AnaptysBio Price Target to $21 From $28, Maintains Neutral Rating	Nov. 01	MT
Wedbush Lowers AnaptysBio's PT to $18 From $26, Adjusts Launch Estimates, Addition of Ulcerative Colitis for Rosnilimab; Keeps Neutral Rating	23-10-26	MT
Transcript : AnaptysBio, Inc. - Special Call	23-10-25
AnaptysBio's Phase 3 Trial of Imsidolimab to Treat Generalized Pustular Psoriasis Meets Primary Endpoint	23-10-09	MT
Anaptys Sees Positive Trial Results for Imsidolimad Psoriasis Treatment	23-10-09	DJ
AnaptysBio's skin disease drug meets main goal in late-stage study	23-10-09	RE
AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis	23-10-09	CI
AnaptysBio Names John Orwin as Board Chairman	23-09-18	MT

Chart AnaptysBio, Inc.

Duration

Period

More charts

Company Profile

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for AnaptysBio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21 USD

Average target price

43.5 USD

Spread / Average Target

+107.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANAPTYSBIO, INC.	-1.96%	574M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs